Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study

Introduction: Immune checkpoint inhibitors (ICIs) have become the standard of treatment for patients with non-small cell lung cancer (NSCLC). However, there are still many uncertainties regarding the selection of the patient who could benefit more from this treatment. This study aims to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Quaquarini, Erica, Sottotetti, Federico, Agustoni, Francesco, Pozzi, Emma, Malovini, Alberto, Teragni, Cristina Maria, Palumbo, Raffaella, Saltalamacchia, Giuseppe, Tagliaferri, Barbara, Balletti, Emanuela, Rinaldi, Pietro, Canino, Costanza, Pedrazzoli, Paolo, Bernardo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144987/
https://www.ncbi.nlm.nih.gov/pubmed/35629102
http://dx.doi.org/10.3390/jpm12050679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144987/
https://www.ncbi.nlm.nih.gov/pubmed/35629102
http://dx.doi.org/10.3390/jpm12050679

Ejemplares similares